As of June 30, 2026, Skye Bioscience, Inc. carries a market capitalization of 24.37M, placing it among publicly traded companies globally. Its enterprise value stands at 14.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 24.37M |
| Enterprise Value | 14.48M |
Skye Bioscience, Inc.'s next confirmed earnings release is scheduled for March 25, 2027.
| Earnings Date | 3/25/2027 |
As of June 30, 2026, Skye Bioscience, Inc. has 4.39M shares outstanding.
| Shares Outstanding | 4.39M |
These figures are as of June 30, 2026.
| PB Ratio | -48.99 |
| P/TBV Ratio | -48.99 |
| P/FCF Ratio | -0.71 |
| P/OCF Ratio | -0.71 |
As of June 30, 2026, Skye Bioscience, Inc. maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -35.94, indicating conservative leverage, while an interest coverage ratio of -9,313.63 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.95 |
| Quick Ratio | 0.87 |
| Debt / Equity | -35.94 |
| Interest Coverage | -9,313.63 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -159.80, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -159.80 |
| Employee Count | 13.00 |
Over the twelve months ended June 30, 2026, Skye Bioscience, Inc. recorded 3,400.00 in income tax expense. The company reported a pretax loss of -50.49M and -50.49M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 3,400.00 |
As of the close on November 16, 2026, Skye Bioscience, Inc.'s stock has declined approximately 89.76% over the past 52 weeks. The 50-day moving average sits at 1.54, while the 200-day moving average is 4.47.
| 52-Week Price Change | -89.76% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 4.47 |
Over the twelve months ended June 30, 2026, Skye Bioscience, Inc. generated - - in revenue and converted that into -50.49M in net income, yielding earnings per share of -10.18. EBITDA reached -51.21M, while operating income came in at -48.65M.
| Operating Income | -48.65M |
| Pretax Income | -50.49M |
| Net Income | -50.49M |
| EBITDA | -51.21M |
| EBIT | -51.90M |
| Earnings Per Share (EPS) | -10.18 |
As of June 30, 2026, Skye Bioscience, Inc. holds 10.06M in cash and equivalents against 178,746.00 in total debt, resulting in a net debt position of -7.93M. Total book value stands at -497,307.00, with working capital of -572,215.00 providing operational flexibility.
| Cash & Cash Equivalents | 10.06M |
| Total Debt | 178,746.00 |
| Net Debt | -7.93M |
| Equity (Book Value) | -497,307.00 |
| Book Value Per Share | -0.11 |
| Working Capital | -572,215.00 |
Skye Bioscience, Inc. produced -38.81M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -38.81M - equivalent to -7.82 per share.
| Operating Cash Flow | -38.81M |
| Free Cash Flow | -38.81M |
| FCF Per Share | -7.82 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -141.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Skye Bioscience, Inc. shareholders.
| Shareholder Yield | 0.66 |
| FCF Yield | -141.08 |
Skye Bioscience, Inc.'s most recent stock split took place on August 24, 2026 with a 8:1 split ratio.
| Last Split Date | 8/24/2026 |
| Split Ratio | 8:1 |
As of June 30, 2026, Skye Bioscience, Inc. has an Altman Z-Score of -40.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -40.01 |